AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios. Revenue rose 12% to $15 billion, ...
Pharmaceutical company AbbVie (NYSE:ABBV) in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-GAAP profit of $2.65 per share was 0.7% below analysts’ consensus estimates. Is now ...
The intersections between neuroscience and immunology – neuroimmunology – have gained increasing attention in recent years. Researchers are discovering how immune cells regulate diverse aspects of ...
AbbVie reported 9.1% revenue growth and a 30.9% adjusted operating margin (including deal-related in-process research and development expense) in the third quarter. Management slightly raised ...
AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios. Revenue rose 12% to $15 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results